AnaptysBio Inc
Research AnaptysBio Inc (ANAB) on Bullrun: market cap USD 1.70B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANAB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.70B
- Financial periodQ1 2026
- RevenueUSD 25.56M
- Net income-USD 26.79M
- Free cash flowUSD 4.41M
Valuation Snapshot
latest market cap is USD 1.70B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 234.60M | -USD 13.23M | USD 19.61M | n/a | -0.46 | USD 238.20M | USD 14.11M | USD 37.21M |
| FY2024 | USD 91.28M | -USD 145.23M | -USD 135.70M | n/a | -5.12 | USD 123.08M | USD 16.04M | USD 70.87M |
| FY2023 | USD 17.16M | -USD 163.62M | -USD 121.61M | n/a | -6.08 | USD 35.97M | USD 17.81M | USD 88.10M |
| FY2022 | USD 10.29M | -USD 128.72M | -USD 73.95M | n/a | -4.57 | USD 71.31M | USD 19.45M | USD 262.10M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.70B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 905.57M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 269.08M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 379.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 587.40M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 640.58M | n/a | n/a | n/a |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AnaptysBio Inc's market cap?
AnaptysBio Inc's market capitalization is USD 1.70B.
What does AnaptysBio Inc do?
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.